NASDAQ: PHIOPhio Pharmaceuticals Corp Stock Ownership - Who owns Phio Pharmaceuticals?
Insider buying vs selling
Have Phio Pharmaceuticals Corp insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Robert J. Bitterman | Chairman Pres CEO | 2025-06-10 | 2,000 | $2.42 | $4.84kBuy |
| Robert L. Ferrara | Director | 2025-06-10 | 2,500 | $2.42 | $6.05kBuy |
| Robert J. Bitterman | Chairman Pres CEO | 2025-06-09 | 1,500 | $2.75 | $4.13kBuy |
| Robert J. Bitterman | Chairman Pres CEO | 2025-05-22 | 1,200 | $1.78 | $2.14kBuy |
| Robert J. Bitterman | Chairman Pres CEO | 2025-05-21 | 3,000 | $1.77 | $5.31kBuy |
| Robert L. Ferrara | Director | 2025-05-20 | 2,500 | $1.82 | $4.55kBuy |
PHIO insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when PHIO insiders and whales buy or sell their stock.
PHIO Shareholders
What type of owners hold Phio Pharmaceuticals Corp stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Opko Health Inc | 1,401.40% | 67,241,380 | $152.64M | Insider |
| Sellas Life Sciences Group Inc | 675.12% | 32,393,095 | $73.53M | Insider |
| Advanced Rna Technologies LLC | 25.46% | 1,221,723 | $2.77M | Insider |
| Alexey Eliseev | 19.81% | 950,312 | $2.16M | Insider |
| John A. Barrett | 4.65% | 222,991 | $506.19k | Insider |
| Gerrit Dispersyn | 4.43% | 212,327 | $481.98k | Insider |
| Geode Capital Management LLC | 0.87% | 41,586 | $94.40k | Institution |
| Cetera Investment Advisers | 0.80% | 38,500 | $87.40k | Institution |
| Robert J. Bitterman | 0.57% | 27,149 | $61.63k | Insider |
| H. Paul Dorman | 0.42% | 20,370 | $46.24k | Insider |
PHIO vs Biotech Stocks
Phio Pharmaceuticals Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.